FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
NEW YORK and PITTSBURGH, Dec. 2 /PRNewswire-FirstCall/ -- Forest
Laboratories, Inc. (NYSE: FRX ) and Mylan Inc. (NYSE: MYL ) announced that
Mylan has received an approvable letter from the U.S. Food and Drug
Administration (FDA) in response to its New Drug Application (NDA) for
USPTO Confirms Validity of Bystolic(R) Patent
Forest licensed U.S. and Canadian rights to nebivolol
from Mylan Laboratories Inc. in January 2006. Forest markets nebivolol
under the Bystolic trademark in the U.S. Mylan licensed the U.S. and Canadian rights to nebivolol
from Janssen Pharmaceutica N.V. in February 2001, ...
Hypertension Drug of Choice for African Americans
...nal Society on Hypertension in Blacks (ISHIB2005), nebivolol
was shown to be statistically significantly better...f the study, he also added: “This study shows that nebivolol
lowered blood pressure in a dose-dependent manner ...ces in the incidence of adverse events between the nebivolol
and placebo groups. The most commonly reported adv...
Nebivolol in Medical Technology
UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX ) today announced the results of a double-blind, randomized,
placebo-controlled clinical trial, published in the November 2007 issue of
the Journal of Clinical Hypertension, which demonstrated that nebivolol
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure
as Long-Term Monotherapy and in Combination Therapy
Data Also Show Nebivolol
Lowers Blood Pressure in Obese and
Non-Obese Hypertensive Patients
CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- Forest
Laboratories, Inc. today presented positive data from two clinical
studies and one pooled analysis of nebivolol, a selective beta
1-blocker with vasodi...
Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
...stage I-II hypertension.
The study also found that nebivolol
was well tolerated in comparison to
placebo, with ...randomly assigned to receive once-daily
placebo or nebivolol
at a 2.5, 5, 10, 20, or 40 mg dose. Among the 259
...-week therapy, by comparison to placebo
significantly reduced sitting diastolic blood pres...
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
adverse changes in blood glucose levels. nebivolol
is currently under
review by the U.S. Food and Dru... Maine Clinical Research. "As we saw in
the study, nebivolol
demonstrated efficacy with a low incidence of side...significant changes in glucose levels, which makes nebivolol
patients with certain metabolic disorder...
Nebivolol in Medical Dictionary
... Forum (GIF) Proliferation Resistance & Physical Protection (PRPP) Working Group ... et al., Approaches to Evaluation of Proliferation ... nebivolol
inhibited accelerated haCSMC proliferation even in the presence of ... This involves proliferation , chemotactic migration into the intimal layers ...
Nebivolol in Biological Technology